Sustained delivery of a broadly neutralizing antibody in nonhuman primates confers long-term protection against simian/human immunodeficiency virus infection

Kevin O. Saunders, Amarendra Pegu, Ivelin S. Georgiev, Ming Zeng, M. Gordon Joyce, Zhi Yong Yang, Sung Youl Ko, Xuejun Chen, Stephen D. Schmidt, Ashley T. Haase, John Paul Todd, Saran Bao, Peter D. Kwong, Srinivas S. Rao, John R. Mascola, Gary J. Nabel

Research output: Contribution to journalArticle

Abstract

Pathogen-specific neutralizing antibodies protect against many viral infections and can potentially prevent human immunodeficiency virus (HIV) transmission in humans. However, neutralizing antibodies have so far only been shown to protect nonhuman primates (NHP) against lentiviral infection when given shortly before challenge. Thus, the clinical utility and feasibility of passive antibody transfer to confer long-term protection against HIV-1 are still debated. Here, we investigate the potential of a broadly neutralizing HIV-1 antibody to provide long-term protection in a NHP model of HIV-1 infection. A human antibody was simianized to avoid immune rejection and used to sustain therapeutic levels for ~5 months. Two months after the final antibody administration, animals were completely protected against viral challenge. These findings demonstrate the feasibility and potential of long-term passive antibody for protection against HIV-1 in humans and provide a model to test antibody therapies for other diseases in NHP.

Original languageEnglish (US)
Pages (from-to)5895-5903
Number of pages9
JournalJournal of Virology
Volume89
Issue number11
DOIs
StatePublished - 2015
Externally publishedYes

Fingerprint

Simian Immunodeficiency Virus
HIV infections
Virus Diseases
Neutralizing Antibodies
neutralizing antibodies
Primates
HIV
HIV-1
Human immunodeficiency virus 1
antibodies
Antibodies
Passive Immunization
infection
therapeutics
Human immunodeficiency virus
virus transmission
neutralization
animal models
Therapeutics
Infection

ASJC Scopus subject areas

  • Immunology
  • Virology

Cite this

Sustained delivery of a broadly neutralizing antibody in nonhuman primates confers long-term protection against simian/human immunodeficiency virus infection. / Saunders, Kevin O.; Pegu, Amarendra; Georgiev, Ivelin S.; Zeng, Ming; Gordon Joyce, M.; Yang, Zhi Yong; Ko, Sung Youl; Chen, Xuejun; Schmidt, Stephen D.; Haase, Ashley T.; Todd, John Paul; Bao, Saran; Kwong, Peter D.; Rao, Srinivas S.; Mascola, John R.; Nabel, Gary J.

In: Journal of Virology, Vol. 89, No. 11, 2015, p. 5895-5903.

Research output: Contribution to journalArticle

Saunders, KO, Pegu, A, Georgiev, IS, Zeng, M, Gordon Joyce, M, Yang, ZY, Ko, SY, Chen, X, Schmidt, SD, Haase, AT, Todd, JP, Bao, S, Kwong, PD, Rao, SS, Mascola, JR & Nabel, GJ 2015, 'Sustained delivery of a broadly neutralizing antibody in nonhuman primates confers long-term protection against simian/human immunodeficiency virus infection', Journal of Virology, vol. 89, no. 11, pp. 5895-5903. https://doi.org/10.1128/JVI.00210-15
Saunders, Kevin O. ; Pegu, Amarendra ; Georgiev, Ivelin S. ; Zeng, Ming ; Gordon Joyce, M. ; Yang, Zhi Yong ; Ko, Sung Youl ; Chen, Xuejun ; Schmidt, Stephen D. ; Haase, Ashley T. ; Todd, John Paul ; Bao, Saran ; Kwong, Peter D. ; Rao, Srinivas S. ; Mascola, John R. ; Nabel, Gary J. / Sustained delivery of a broadly neutralizing antibody in nonhuman primates confers long-term protection against simian/human immunodeficiency virus infection. In: Journal of Virology. 2015 ; Vol. 89, No. 11. pp. 5895-5903.
@article{a00fe0b75908453dada1ea871c4a749c,
title = "Sustained delivery of a broadly neutralizing antibody in nonhuman primates confers long-term protection against simian/human immunodeficiency virus infection",
abstract = "Pathogen-specific neutralizing antibodies protect against many viral infections and can potentially prevent human immunodeficiency virus (HIV) transmission in humans. However, neutralizing antibodies have so far only been shown to protect nonhuman primates (NHP) against lentiviral infection when given shortly before challenge. Thus, the clinical utility and feasibility of passive antibody transfer to confer long-term protection against HIV-1 are still debated. Here, we investigate the potential of a broadly neutralizing HIV-1 antibody to provide long-term protection in a NHP model of HIV-1 infection. A human antibody was simianized to avoid immune rejection and used to sustain therapeutic levels for ~5 months. Two months after the final antibody administration, animals were completely protected against viral challenge. These findings demonstrate the feasibility and potential of long-term passive antibody for protection against HIV-1 in humans and provide a model to test antibody therapies for other diseases in NHP.",
author = "Saunders, {Kevin O.} and Amarendra Pegu and Georgiev, {Ivelin S.} and Ming Zeng and {Gordon Joyce}, M. and Yang, {Zhi Yong} and Ko, {Sung Youl} and Xuejun Chen and Schmidt, {Stephen D.} and Haase, {Ashley T.} and Todd, {John Paul} and Saran Bao and Kwong, {Peter D.} and Rao, {Srinivas S.} and Mascola, {John R.} and Nabel, {Gary J.}",
year = "2015",
doi = "10.1128/JVI.00210-15",
language = "English (US)",
volume = "89",
pages = "5895--5903",
journal = "Journal of Virology",
issn = "0022-538X",
publisher = "American Society for Microbiology",
number = "11",

}

TY - JOUR

T1 - Sustained delivery of a broadly neutralizing antibody in nonhuman primates confers long-term protection against simian/human immunodeficiency virus infection

AU - Saunders, Kevin O.

AU - Pegu, Amarendra

AU - Georgiev, Ivelin S.

AU - Zeng, Ming

AU - Gordon Joyce, M.

AU - Yang, Zhi Yong

AU - Ko, Sung Youl

AU - Chen, Xuejun

AU - Schmidt, Stephen D.

AU - Haase, Ashley T.

AU - Todd, John Paul

AU - Bao, Saran

AU - Kwong, Peter D.

AU - Rao, Srinivas S.

AU - Mascola, John R.

AU - Nabel, Gary J.

PY - 2015

Y1 - 2015

N2 - Pathogen-specific neutralizing antibodies protect against many viral infections and can potentially prevent human immunodeficiency virus (HIV) transmission in humans. However, neutralizing antibodies have so far only been shown to protect nonhuman primates (NHP) against lentiviral infection when given shortly before challenge. Thus, the clinical utility and feasibility of passive antibody transfer to confer long-term protection against HIV-1 are still debated. Here, we investigate the potential of a broadly neutralizing HIV-1 antibody to provide long-term protection in a NHP model of HIV-1 infection. A human antibody was simianized to avoid immune rejection and used to sustain therapeutic levels for ~5 months. Two months after the final antibody administration, animals were completely protected against viral challenge. These findings demonstrate the feasibility and potential of long-term passive antibody for protection against HIV-1 in humans and provide a model to test antibody therapies for other diseases in NHP.

AB - Pathogen-specific neutralizing antibodies protect against many viral infections and can potentially prevent human immunodeficiency virus (HIV) transmission in humans. However, neutralizing antibodies have so far only been shown to protect nonhuman primates (NHP) against lentiviral infection when given shortly before challenge. Thus, the clinical utility and feasibility of passive antibody transfer to confer long-term protection against HIV-1 are still debated. Here, we investigate the potential of a broadly neutralizing HIV-1 antibody to provide long-term protection in a NHP model of HIV-1 infection. A human antibody was simianized to avoid immune rejection and used to sustain therapeutic levels for ~5 months. Two months after the final antibody administration, animals were completely protected against viral challenge. These findings demonstrate the feasibility and potential of long-term passive antibody for protection against HIV-1 in humans and provide a model to test antibody therapies for other diseases in NHP.

UR - http://www.scopus.com/inward/record.url?scp=84929613728&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84929613728&partnerID=8YFLogxK

U2 - 10.1128/JVI.00210-15

DO - 10.1128/JVI.00210-15

M3 - Article

VL - 89

SP - 5895

EP - 5903

JO - Journal of Virology

JF - Journal of Virology

SN - 0022-538X

IS - 11

ER -